Keshi Wang, PhD
Senior Vice President, DMPK and Clinical Pharmacology
Keshi joined BridgeBio Pharma in April 2022 and is now Senior Vice President of DMPK and Clinical Pharmacology at BBOT. Prior to joining BridgeBio, Keshi was Vice President of DMPK and Clinical Pharmacology at NiKang Therapeutics from 2020 to 2022, Senior Director at Peloton Therapeutics from 2013 to 2020, and Investigator III at Novartis/Chiron from 1999 to 2013.
Keshi holds a PhD in Organic Chemistry from Washington University in St. Louis and did his postdoctoral training at UC San Francisco.